Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2025-02-11 00:00:00 ET · period of report 2025-02-10 · accession 0001724521-25-000032 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-11 | 2025-02-10 | RCUS | Markus Richard | Chief Medical Off | A - Grant | $0.00 | +75.2K | 75.2K | New | $0 |
| D | 2025-02-11 | 2025-02-10 | RCUS | Markus Richard | Chief Medical Off | A - Grant | $0.00 | +305.3K | 305.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-10 | A | A | 75,193 | $0.00 | 75,193 | D | — | — | (F1) Represents the grant of restricted stock units that vest in four equal annual installments beginning March 15, 2026, subject to the Reporting Person's continued service to the Company. |
| 2 | Derivative | Stock Option (right to buy) | 2025-02-10 | A | A | 305,328 | $0.00 | 305,328 | D | $12.45 · — to 2035-01-30 | 305,328 Common Stock | (F2) The option becomes exercisable in 48 equal monthly installments after February 1, 2025, subject to the Reporting Person's continued service to the Company |